Ignite Creation Date:
2025-12-25 @ 12:31 AM
Ignite Modification Date:
2026-01-06 @ 4:57 AM
Study NCT ID:
NCT03398967
Status:
UNKNOWN
Last Update Posted:
2018-01-16
First Post:
2018-01-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
Sponsor:
Chinese PLA General Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-01-02
Start Date Type:
ACTUAL
Primary Completion Date:
2022-05-20
Primary Completion Date Type:
ESTIMATED
Completion Date:
2022-05-20
Completion Date Type:
ESTIMATED
First Submit Date:
2018-01-08
First Submit QC Date:
None
Study First Post Date:
2018-01-16
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-01-08
Last Update Post Date:
2018-01-16
Last Update Post Date Type:
ACTUAL